Chong-Bo Zhao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2146100/publications.pdf

Version: 2024-02-01

101	1,501	377584	488211
papers	citations	21 h-index	31 g-index

108	108	108	2069
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Journal of Neurology, 2022, 269, 1250-1263.	1.8	10
2	Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases. Autoimmunity Reviews, 2022, 21, 102931.	2.5	7
3	Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets. Journal of Neuroimmunology, 2022, 362, 577787.	1.1	4
4	A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation. Frontiers in Immunology, 2022, 13, 746068.	2.2	2
5	Late onset neuromyelitis optica spectrum disorder with antiâ€aquaporin 4 and antiâ€myelin oligodendrocyte glycoprotein antibodies. European Journal of Neurology, 2022, 29, 1128-1135.	1.7	6
6	Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity Reviews, 2022, 21, 103032.	2.5	1
7	Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis. Orphanet Journal of Rare Diseases, 2022, 17, 52.	1.2	7
8	Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models. Frontiers in Immunology, 2022, 13, 873576.	2.2	8
9	Pneumonia and systemic inflammatory response syndrome as predictors for difficult-/prolonged-weaning after invasive ventilation in myasthenic crisis: A retrospective analysis of a Chinese cohort. Neuromuscular Disorders, 2022, 32, 220-229.	0.3	1
10	A case of A133V genetic Creutzfeldtâ€"Jakob disease presenting with bilateral thalamic lesions and atypical clinical features. Acta Neurologica Belgica, 2022, , 1.	0.5	0
11	Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China. Frontiers in Neurology, 2022, 13, 879261.	1.1	2
12	Efficacy and safety of rehabilitation exercise in neuromyelitis optica spectrum disorder during the acute phase: A prospective cohort study. Multiple Sclerosis and Related Disorders, 2022, 61, 103726.	0.9	3
13	Telemedicine application in patients with chronic disease: a systematic review and meta-analysis. BMC Medical Informatics and Decision Making, 2022, 22, 105.	1.5	28
14	Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder. European Journal of Neurology, 2022, 29, 2343-2354.	1.7	7
15	Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study. Neurology and Therapy, 2022, 11, 815-834.	1.4	27
16	<scp>Melkersonâ€Rosenthal</scp> syndrome complicated by inflammatory myopathy. Muscle and Nerve, 2022, 66, .	1.0	0
17	The effect of integrated health care in patients with hypertension and diabetes: a systematic review and meta-analysis. BMC Health Services Research, 2022, 22, 603.	0.9	1
18	Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis. BMC Immunology, 2022, 23, .	0.9	10

#	Article	IF	Citations
19	Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study. Clinical Immunology, 2022, 241, 109058.	1.4	7
20	The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China. Multiple Sclerosis and Related Disorders, 2022, 66, 104023.	0.9	3
21	Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 53-61.	0.9	15
22	Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporinâ€4 antibody: A comparative study in Chinese Han patients. European Journal of Neurology, 2021, 28, 1308-1315.	1.7	14
23	The therapeutic efficacy of Xuanfei Baidu Formula combined with conventional drug in the treatment of coronavirus disease 2019. Medicine (United States), 2021, 100, e24129.	0.4	5
24	Neurofilament light is a novel biomarker for mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. Scientific Reports, 2021, 11, 2001.	1.6	5
25	Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2021, 48, 102707.	0.9	5
26	Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Frontiers in Immunology, 2021, 12, 647618.	2.2	32
27	Shortâ€term effect of lowâ€dose rituximab on myasthenia gravis with muscleâ€specific tyrosine kinase antibody. Muscle and Nerve, 2021, 63, 824-830.	1.0	10
28	The role of innate immunity in myasthenia gravis. Autoimmunity Reviews, 2021, 20, 102800.	2.5	3
29	Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis. Journal of Translational Medicine, 2021, 19, 285.	1.8	4
30	COVID-19 Vaccination Attitudes With Neuromyelitis Optica Spectrum Disorders: Vaccine Hesitancy and Coping Style. Frontiers in Neurology, 2021, 12, 717111.	1.1	9
31	Kv3.1 channelopathy: a novel loss-of-function variant and the mechanistic basis of its clinical phenotypes. Annals of Translational Medicine, 2021, 9, 1397-1397.	0.7	8
32	Molecular landscape of DYSF mutations in dysferlinopathy: From a Chinese multicenter analysis to a worldwide perspective. Human Mutation, 2021, 42, 1615-1623.	1.1	6
33	Inâ€depth peripheral CD4⁺ T profile correlates with myasthenic crisis. Annals of Clinical and Translational Neurology, 2021, 8, 749-762.	1.7	14
34	5â€² UTR CGG repeat expansion inGIPC1is associated with oculopharyngodistal myopathy. Brain, 2021, 144, 601-614.	3.7	44
35	Double-blinded, randomized, placebo-controlled phase 2 study of FCRN antagonist batoclimab in Chinese generalized myasthenia gravis. Journal of the Neurological Sciences, 2021, 429, 118421.	0.3	0
36	Comorbid Autoimmune Diseases in Patients With Myasthenia Gravis: A Retrospective Cross-Sectional Study of a Chinese Cohort. Frontiers in Neurology, 2021, 12, 790941.	1.1	8

#	Article	IF	Citations
37	Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2021, 12, 725700.	1.1	8
38	The Alteration of Circulating Lymphocyte Subsets During Tacrolimus Therapy in Neuromyelitis Optica Spectrum Disorder and Its Correlation With Clinical Outcomes. Frontiers in Neurology, 2021, 12, 816721.	1.1	3
39	Lowâ€dose rituximab every 6â€‰months for the treatment of acetylcholine receptorâ€“positive refractory generalized myasthenia gravis. Muscle and Nerve, 2020, 61, 311-315.	1.0	23
40	Electromyographic Features in a Chinese Cohort With Hereditary Skeletal Muscle Channelopathies. Journal of Clinical Neurophysiology, 2020, 37, 231-238.	0.9	2
41	Molecular landscape of CAPN3 mutations in limb-girdle muscular dystrophy type R1: from a Chinese multicentre analysis to a worldwide perspective. Journal of Medical Genetics, 2020, 58, jmedgenet-2020-107159.	1.5	4
42	Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience. Multiple Sclerosis and Related Disorders, 2020, 46, 102542.	0.9	24
43	Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients. Journal of Neuroimmunology, 2020, 348, 577383.	1.1	11
44	Genotypeâ€“phenotype correlations in recessive titinopathies. Genetics in Medicine, 2020, 22, 2029-2040.	1.1	35
45	Therapeutic and Immunoregulatory Effects of Tacrolimus in Patients with Refractory Generalized Myasthenia Gravis. European Neurology, 2020, 83, 500-507.	0.6	3
46	Gender differences in quality of life among patients with myasthenia gravis in China. Health and Quality of Life Outcomes, 2020, 18, 296.	1.0	25
47	Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays. Journal of Neuroimmunology, 2020, 349, 577403.	1.1	3
48	Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China. European Neurology, 2020, 83, 182-188.	0.6	12
49	Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 453-466.	0.6	7
50	Congenital myasthenia syndrome in a Chinese family with mutations in MUSK: A hotspot mutation and literature review. Journal of Clinical Neuroscience, 2020, 76, 161-165.	0.8	7
51	Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. British Journal of Ophthalmology, 2019, 103, 789-796.	2.1	55
52	Novel mutations in HINT1 gene cause the autosomal recessive axonal neuropathy with neuromyotonia. European Journal of Medical Genetics, 2019, 62, 190-194.	0.7	23
53	The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells. Journal of Thoracic Disease, 2019, 11, 2315-2323.	0.6	9
54	HLA in myasthenia gravis: From superficial correlation to underlying mechanism. Autoimmunity Reviews, 2019, 18, 102349.	2.5	25

#	Article	IF	Citations
55	Clinical spectrum and gene mutations in a Chinese cohort with anoctaminopathy. Neuromuscular Disorders, 2019, 29, 628-633.	0.3	9
56	Neutral lipid storage disease with myopathy in China: a large multicentric cohort study. Orphanet Journal of Rare Diseases, 2019, 14, 234.	1.2	15
57	Predictive Score for In-Hospital Mortality of Myasthenic Crisis: A Retrospective Chinese Cohort Study. European Neurology, 2019, 81, 287-293.	0.6	10
58	Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis. Journal of Neuroimmunology, 2019, 332, 216-223.	1.1	23
59	Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer. Journal of Clinical Neuroscience, 2019, 65, 41-45.	0.8	9
60	Identification of gene mutations in patients with primary periodic paralysis using targeted next-generation sequencing. BMC Neurology, 2019, 19, 92.	0.8	14
61	Inhibition of ROCK activity regulates the balance of Th1, Th17 and Treg cells in myasthenia gravis. Clinical Immunology, 2019, 203, 142-153.	1.4	18
62	Loss-of-function mutations in Lysyl-tRNA synthetase cause various leukoencephalopathy phenotypes. Neurology: Genetics, 2019, 5, e565.	0.9	9
63	Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis. Journal of Clinical Neuroscience, 2019, 63, 160-167.	0.8	18
64	Cell-Based Versus Enzyme-Linked Immunosorbent Assay for the Detection of Acetylcholine Receptor Antibodies in Chinese Juvenile Myasthenia Gravis. Pediatric Neurology, 2019, 98, 74-79.	1.0	9
65	Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network metaâ€analysis. CNS Neuroscience and Therapeutics, 2019, 25, 647-658.	1.9	14
66	Neurolymphomatosis caused by diffuse large B-cell lymphoma presenting as isolated brachial plexopathy. Chinese Medical Journal, 2019, 132, 2762-2764.	0.9	1
67	HLA typing using next-generation sequencing for Chinese juvenile- and adult-onset myasthenia gravis patients. Journal of Clinical Neuroscience, 2019, 59, 179-184.	0.8	8
68	GNE myopathy in Chinese population: hotspot and novel mutations. Journal of Human Genetics, 2019, 64, 11-16.	1.1	18
69	Missense mutations in LAMA2 causing a new phenotype of mild cognitive impairment, proximal myopathy, seizure, and severe leukoencephalopathy: A case report and protein analysis. , 2019, 38, 100-108.		2
70	A randomized control study on the efficacy of thymectomy in patients with nonthymomatous (without chest tumor) myasthenia gravis. Annals of Indian Academy of Neurology, 2019, 23, 141-144.	0.2	0
71	Palpebral portion of the orbicularis oculi muscle to repetitive nerve stimulation testing: A potential assessment indicator in patients with generalized myasthenia gravis. Journal of Clinical Neuroscience, 2018, 48, 238-242.	0.8	2
72	Exertional myalgia, contractures and annular erythema in a patient with muscle lactate dehydrogenase (LDH) deficiency. Neuromuscular Disorders, 2018, 28, 59.	0.3	1

#	Article	IF	Citations
73	Giant Axonal Neuropathy with Unusual Neuroimagings Caused by Compound Heterozygous Mutations in GAN Gene. Chinese Medical Journal, 2018, 131, 2371-2372.	0.9	3
74	Statin-naÃ¯ve anti-HMGCR antibody-mediated necrotizing myopathy in China. Journal of Clinical Neuroscience, 2018, 57, 13-19.	0.8	18
75	Fatty infiltration evaluation and selective pattern characterization of lower limbs in limbâ€girdle muscular dystrophy type 2A by muscle magnetic resonance imaging. Muscle and Nerve, 2018, 58, 536-541.	1.0	22
76	Hypokalaemic periodic paralysis and myotonia in a patient with homozygous mutation p.R1451L in NaV1.4. Scientific Reports, 2018, 8, 9714.	1.6	20
77	The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients. Journal of Neuroimmunology, 2017, 302, 49-55.	1.1	29
78	MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients. Journal of Neuroimmunology, 2017, 305, 19-28.	1.1	84
79	Increased cerebral blood flow as a predictor of episodes in MELAS using multimodal MRI. Journal of Magnetic Resonance Imaging, 2017, 46, 915-918.	1.9	7
80	Isaacs syndrome with CASPR2 antibody: A series of three cases. Journal of Clinical Neuroscience, 2017, 41, 63-66.	0.8	19
81	Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis. Journal of Neuroimmunology, 2017, 311, 14-21.	1.1	47
82	Novel mutations in the C-terminal region of GMPPB causing limb-girdle muscular dystrophy overlapping with congenital myasthenic syndrome. Neuromuscular Disorders, 2017, 27, 557-564.	0.3	27
83	Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies. Multiple Sclerosis and Related Disorders, 2017, 18, 90-92.	0.9	52
84	Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. Therapeutic Advances in Neurological Disorders, 2017, 10, 315-325.	1.5	30
85	Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. Journal of Neurology, 2017, 264, 2191-2200.	1.8	23
86	Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology, 2017, 56, 287-293.	0.9	64
87	Neurolymphomatosis Caused by Nasal-type Extranodal Natural Killer/T-cell Lymphoma. Chinese Medical Journal, 2017, 130, 625-626.	0.9	4
88	Leukodystrophy without Ovarian Failure Caused by Compound Heterozygous Alanyl-tRNA Synthetase 2 Mutations. Chinese Medical Journal, 2017, 130, 3021-3022.	0.9	3
89	Novel SEA and LG2 Agrin mutations causing congenital Myasthenic syndrome. Orphanet Journal of Rare Diseases, 2017, 12, 182.	1.2	18
90	A Case of Intracranial Dural Arteriovenous Fistula Mimicking Brainstem Tumor. Chinese Medical Journal, 2017, 130, 2519-2520.	0.9	4

#	Article	IF	Citations
91	Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma. Journal of Thoracic Disease, 2016, 8, 314-322.	0.6	32
92	Clinical features and long exercise test in Chinese patients with Andersenâ€Tawil syndrome. Muscle and Nerve, 2016, 54, 1059-1063.	1.0	17
93	Neuromyelitis optica accompanied by nephrotic syndrome and autoimmune-related pancytopenia. Multiple Sclerosis and Related Disorders, 2016, 7, 8-11.	0.9	6
94	Identification of LAMP2 Mutations in Early-Onset Danon Disease With Hypertrophic Cardiomyopathy by Targeted Next-Generation Sequencing. American Journal of Cardiology, 2016, 118, 888-894.	0.7	29
95	Multiple deep white matter lesions mimic multiple sclerosis as an unusual complication of left atrial myxoma. Multiple Sclerosis Journal, 2015, 21, 108-110.	1.4	3
96	New disease allele and de novo mutation indicate mutational vulnerability of titin exon 343 in hereditary myopathy with early respiratory failure. Neuromuscular Disorders, 2015, 25, 172-176.	0.3	16
97	The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. Journal of Neuroimmunology, 2015, 282, 45-53.	1.1	61
98	Muscle pathology and whole-body MRI in a polyglucosan myopathy associated with a novel glycogenin-1 mutation. Neuromuscular Disorders, 2015, 25, 780-785.	0.3	28
99	Giant cell polymyositis associated with myasthenia gravis and thymoma. Journal of Clinical Neuroscience, 2014, 21, 2252-2254.	0.8	11
100	Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action. Journal of Clinical Neuroscience, 2014, 21, 1570-1574.	0.8	24
101	HLA-DQA1*03:02/DQB1*03:03:02 is strongly associated with susceptibility to childhood-onset ocular myasthenia gravis in Southern Han Chinese. Journal of Neuroimmunology, 2012, 247, 81-85.	1.1	22